Welcome to our dedicated page for Ibio news (Ticker: IBIO), a resource for investors and traders seeking the latest updates and insights on Ibio stock.
iBio, Inc. (NASDAQ: IBIO) is an AI-driven biotechnology company developing precision antibody therapies for cardiometabolic diseases, obesity, cancer and other hard-to-treat conditions. The IBIO news feed on Stock Titan aggregates company press releases and other coverage so readers can follow how the business and its preclinical pipeline are evolving over time.
Recent news highlights iBio’s focus on obesity and cardiometabolic disease, including preclinical data for its Activin E antibody candidate IBIO-610 and its long-acting anti-myostatin antibody IBIO-600. The company has reported fat-selective, GLP‑1‑synergistic weight loss in diet-induced obesity mouse models, non-human primate pharmacokinetic data suggesting extended half-life and potential for infrequent dosing, and early evidence that its programs may help preserve lean mass in combination with GLP‑1 therapies. Updates also cover presentations at scientific and investor conferences such as ObesityWeek, PEGS Europe and healthcare-focused investment conferences.
Investors tracking IBIO news will also see announcements about financings, including underwritten public offerings, warrant transactions and private placements with institutional investors, along with disclosures on how proceeds are intended to support preclinical cardiometabolic programs and other pipeline assets. Regulatory and corporate developments reported via Form 8‑K, such as Nasdaq listing compliance notices, annual meeting results and updated corporate presentations, provide additional context on governance and capital markets activity.
By following this IBIO news page, readers can monitor new preclinical data, conference participation, financing transactions and key SEC-reported events that shape iBio’s progress as a preclinical-stage, AI-enabled antibody developer.
iBio, Inc. (IBIO) announced a research collaboration with UT Southwestern to investigate the anti-cancer effects of its IBIO-100 program in solid tumors. The focus will be on cancer-associated fibroblasts (CAFs) and the molecule endostatin E4, which may enhance chemotherapy and immunotherapy outcomes. Tom Isett, iBio's CEO, expressed enthusiasm about the partnership, while Chief Scientific Officer Martin Brenner highlighted the importance of targeting fibrosis for better cancer treatment responses. The research aims to explore how to normalize fibrotic environments without destroying CAFs.
iBio, Inc. (NYSEA:IBIO) will report its fiscal 2022 first quarter financial results after market close on November 15, 2021. The company, known for its sustainable, plant-based FastPharming Manufacturing System, will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss these results and provide a corporate update. Investors can access the live and archived webcast on the company's website. iBio focuses on developing biopharmaceuticals for treating cancers, fibrotic conditions, and infectious diseases.
iBio, Inc. (NYSEA:IBIO) has acquired full ownership of its CDMO subsidiary and U.S. manufacturing rights for its FastPharming System, reducing carrying costs by approximately 67%. The transaction, valued at $28.75 million, was financed through cash and warrants for stock. This move is expected to enhance strategic flexibility and operational growth in Texas, while iBio anticipates sustaining its operations with its current cash position through Q1 2023.
iBio, Inc. (NYSEA:IBIO) urges stockholders to vote “FOR” all proposals in their proxy statement ahead of the December 9, 2021 Annual Meeting. The proposals include amendments to the Company’s Articles of Incorporation requiring majority approval. Stockholders with shares as of October 15, 2021, are eligible to vote. CEO Tom Isett highlights the importance of shareholder participation for strategic growth. A new Q&A page has been created to facilitate communication. Stockholders can access their voting instructions via proxy cards or by contacting Okapi Partners for assistance.
iBio, a developer of biopharmaceuticals, announced its fiscal Q4 and annual results for 2021. Revenues reached $2.4 million, a 50% increase year-over-year, though Q4 revenue dropped to $0.5 million. Key developments include a partnership with RubrYc for an anti-CD25 antibody, expansion into oncology, and progress on the COVID-19 vaccine, IBIO-202. The company's consolidated net loss widened to $23.2 million, influenced by $10.2 million from a legal settlement. iBio's cash position is robust, at $97 million, allowing funding through Q1 2023.
iBio, Inc. (NYSEA:IBIO), a leader in biopharmaceuticals, announced that its Chairman & CEO, Tom Isett, and CSO, Martin Brenner, will engage in a fireside chat at the Cantor Virtual Global Healthcare Conference on September 27, 2021, at 10:00 a.m. ET. This event will focus on the innovative FastPharming Manufacturing System® and the company’s advancements in biopharmaceutical development. The chat will be broadcast live on the company’s website and archived for future access.
iBio, Inc. (NYSEA:IBIO) is set to report its fiscal fourth quarter and full year 2021 financial results on September 27, 2021, before market open. Management will host a webcast and conference call at 8:30 a.m. ET to discuss the results and provide a corporate update. iBio is renowned for its FastPharming Manufacturing System®, focusing on sustainable, plant-based biopharmaceuticals. The company develops proprietary treatments for cancers, fibrotic, and infectious diseases while offering FastPharming Contract Development and Manufacturing Services.
iBio, Inc. (NYSEA:IBIO) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference, taking place virtually from September 13-15, 2021. A pre-recorded presentation by iBio will be available on demand for registered attendees and on their website from September 13. iBio specializes in sustainable, plant-based pharmaceuticals through its FastPharming Manufacturing System®, developing treatments for cancer, fibrotic, and infectious diseases, while also providing contract development services.
iBio, Inc. (NYSE:IBIO) has appointed William D. (Chip) Clark to its Board of Directors, bringing over 30 years of biotechnology experience, particularly in immuno-oncology. His prior leadership at Genocea was marked by a pivotal shift to immuno-oncology, and his insights are expected to support the advancement of IBIO-101 and other therapies. The company aims to leverage its FastPharming Manufacturing System to enhance cancer drug development. The press release also highlights ongoing forward-looking statements regarding regulatory approvals and marketplace acceptance.
iBio licenses a novel antibody targeting regulatory T cells through a worldwide exclusive agreement with RubrYc Therapeutics for RTX-003, enhancing its oncology pipeline. The partnership includes options for additional antibodies from RubrYc's AI-based platform. iBio has acquired an equity stake in RubrYc and is committed to further investment. Preclinical data shows RTX-003 effectively depletes Tregs without blocking IL-2 signaling, promising strong anti-tumor responses. iBio plans to advance RTX-003 to clinical studies as IBIO-101, with IND-enabling studies expected by mid-2022.